Significance of Alectinib-Induced Bradycardia: Rhythm and Reversibility Matter More Than Rate

por Kondapalli, Lavanya, Camidge, D. Ross
Publicado 2023

A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer

por Pacheco, Jose M., Camidge, D. Ross, Doebele, Robert C., Schenk, Erin
Publicado 2019

PD-1/PD-L1 inhibitor activity in patients with gene-rearrangement positive non-small cell lung cancer—an IMMUNOTARGET case series

por Mushtaq, Rao, Cortot, Alexis B., Gautschi, Oliver, Mazieres, Julien, Camidge, D. Ross
Publicado 2022

Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours

por Karp, Daniel D., Camidge, D. Ross, Infante, Jeffery R., Ames, Tyler D., Price, Matthew R., Jimeno, José, Bryce, Alan H.
Publicado 2022

Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer

por Patil, Tejas, Pacheco, Jose M., Dimou, Anastasios, Purcell, William T., Rossi, Candice, Bunn, Paul A., Doebele, Robert C., Camidge, D. Ross, Ferrigno, Lisa
Publicado 2020

Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer

por Hackshaw, Michelle D., Danysh, Heather E., Singh, Jasmeet, Ritchey, Mary E., Ladner, Amy, Taitt, Corina, Camidge, D. Ross, Iwata, Hiroji, Powell, Charles A.
Publicado 2020

A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future

por Ren, Sijia, Xu, Anyi, Lin, Yilian, Camidge, D. Ross, Di Maio, Massimo, Califano, Raffaele, Hida, Toyoaki, Rossi, Antonio, Guibert, Nicolas, Zhu, Chengchu, Shen, Jianfei
Publicado 2021

Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States

por Jahanzeb, Mohammad, Lin, Huamao M, Wu, Yanyu, Zhang, Pingkuan, Gorritz, Magdaliz, McGuiness, Catherine B, Huang, Wei-Ti, Sun, Kainan, Chen, Chi-Chang, Camidge, D Ross
Publicado 2022

Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies

por Powell, C.A., Modi, S., Iwata, H., Takahashi, S., Smit, E.F., Siena, S., Chang, D.-Y., Macpherson, E., Qin, A., Singh, J., Taitt, C., Shire, N., Camidge, D. Ross
Publicado 2022

Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study

por Blais, Normand, Camidge, D. Ross, Jonker, Derek J., Soulières, Denis, Laurie, Scott A., Diab, Sami G., Ruiz-Garcia, Ana, Thall, Aron, Zhang, Ke, Chao, Richard C., Chow, Laura Q.
Publicado 2013

Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial

por Dziadziuszko, Rafal, Peters, Solange, Mok, Tony, Camidge, D. Ross, Gadgeel, Shirish M., Ou, Sai-Hong Ignatius, Konopa, Krzysztof, Noé, Johannes, Nowicka, Malgorzata, Bordogna, Walter, Morcos, Peter N., Smoljanovic, Vlatka, Shaw, Alice T.
Publicado 2022

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer

por Camidge, D. Ross, Berge, Eamon M., Doebele, Robert C., Ballas, Marc S., Jahan, Thierry, Haigentz, Missak, Hoffman, David, Spicer, James, West, Howard, Lee, Pablo, Yang, Ling, Joshi, Adarsh, Gao, Ling, Yurasov, Sergey, Mita, Alain
Publicado 2014

Real-world insights into patients with advanced NSCLC and MET alterations

por Bittoni, Marisa, Yang, James Chih-Hsin, Shih, Jin-Yuan, Peled, Nir, Smit, Egbert F., Camidge, D. Ross, Arasada, Rajeswara Rao, Oksen, Dina, Boutmy, Emmanuelle, Stroh, Christopher, Johne, Andreas, Carbone, David P., Paik, Paul K.
Publicado 2021

Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer

por Davies, Kurtis D., Mahale, Sakshi, Astling, David P., Aisner, Dara L., Le, Anh T., Hinz, Trista K., Vaishnavi, Aria, Bunn, Paul A., Heasley, Lynn E., Tan, Aik-Choon, Camidge, D. Ross, Varella-Garcia, Marileila, Doebele, Robert C.
Publicado 2013

Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer

por Pritchett, Michael A., Camidge, D. Ross, Patel, Manu, Khatri, Jamil, Boniol, Steven, Friedman, Elke K., Khomani, Abderrahim, Dalia, Samir, Baker-Neblett, Katherine, Plagnol, Vincent, Howarth, Karen D., Jones, Gregory R., Rosenfeld, Nitzan, Morris, Clive D., Govindan, Ramaswamy
Publicado 2019

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma

por Camidge, D. Ross, Morgensztern, Daniel, Heist, Rebecca S., Barve, Minal, Vokes, Everett, Goldman, Jonathan W., Hong, David S., Bauer, Todd M., Strickler, John H., Angevin, Eric, Motwani, Monica, Parikh, Apurvasena, Sun, Zhaowen, Bach, Bruce Allen, Wu, Jun, Komarnitsky, Philip B., Kelly, Karen
Publicado 2021

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer

por Camidge, D. Ross, Barlesi, Fabrice, Goldman, Jonathan W., Morgensztern, Daniel, Heist, Rebecca, Vokes, Everett, Spira, Alex, Angevin, Eric, Su, Wu-Chou, Hong, David S., Strickler, John H., Motwani, Monica, Dunbar, Martin, Parikh, Apurvasena, Noon, Elysa, Blot, Vincent, Wu, Jun, Kelly, Karen
Publicado 2023

A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer...

por Reckamp, Karen L., Giaccone, Giuseppe, Camidge, D. Ross, Gadgeel, Shirish M., Khuri, Fadlo R., Engelman, Jeff A., Koczywas, Marianna, Rajan, Arun, Campbell, Alicyn K., Gernhardt, Diana, Ruiz‐Garcia, Ana, Letrent, Stephen, Liang, Jane, Taylor, Ian, O'Connell, Joseph P., Jänne, Pasi A.
Publicado 2014

A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC

por Camidge, D. Ross, Barlesi, Fabrice, Goldman, Jonathan W., Morgensztern, Daniel, Heist, Rebecca, Vokes, Everett, Angevin, Eric, Hong, David S., Rybkin, Igor I., Barve, Minal, Bauer, Todd M., Delmonte, Angelo, Dunbar, Martin, Motwani, Monica, Parikh, Apurvasena, Noon, Elysa, Wu, Jun, Blot, Vincent, Kelly, Karen
Publicado 2021

Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer

por Shaw, Alice T., Gandhi, Leena, Gadgeel, Shirish, Riely, Gregory J., Cetnar, Jeremy, West, Howard, Camidge, D. Ross, Socinski, Mark A., Chiappori, Alberto, Mekhail, Tarek, Chao, Bo H., Borghaei, Hossein, Gold, Kathryn A., Zeaiter, Ali, Bordogna, Walter, Balas, Bogdana, Puig, Oscar, Henschel, Volkmar, Ignatius Ou, Sai-Hong
Publicado 2015